200 related articles for article (PubMed ID: 29020849)
21. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
22. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.
Gkionis L; Campbell RA; Aojula H; Harris LK; Tirella A
Int J Pharm; 2020 Nov; 590():119926. PubMed ID: 33010397
[TBL] [Abstract][Full Text] [Related]
23. Convection enhanced delivery of liposome encapsulated doxorubicin for brain tumour therapy.
Zhan W; Wang CH
J Control Release; 2018 Sep; 285():212-229. PubMed ID: 30009891
[TBL] [Abstract][Full Text] [Related]
24. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
25. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin αvβ3-expressing tumor endothelial cells.
Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2013 Jul; 34(22):5617-27. PubMed ID: 23623323
[TBL] [Abstract][Full Text] [Related]
26. Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue.
Yan Z; Yang Y; Wei X; Zhong J; Wei D; Liu L; Xie C; Wang F; Zhang L; Lu W; He D
Mol Pharm; 2014 Jan; 11(1):218-25. PubMed ID: 24325555
[TBL] [Abstract][Full Text] [Related]
27. Microfluidic synthesis of multifunctional liposomes for tumour targeting.
Ran R; Middelberg APJ; Zhao CX
Colloids Surf B Biointerfaces; 2016 Dec; 148():402-410. PubMed ID: 27639490
[TBL] [Abstract][Full Text] [Related]
28. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor.
Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y
Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533
[TBL] [Abstract][Full Text] [Related]
29. Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity.
Nishida K; Kashiwagi M; Shiba S; Muroki K; Ohishi A; Doi Y; Ando H; Ishida T; Nagasawa K
Toxicol Appl Pharmacol; 2017 Dec; 337():76-84. PubMed ID: 29054682
[TBL] [Abstract][Full Text] [Related]
30. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
31. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
[TBL] [Abstract][Full Text] [Related]
32. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy.
Pasut G; Paolino D; Celia C; Mero A; Joseph AS; Wolfram J; Cosco D; Schiavon O; Shen H; Fresta M
J Control Release; 2015 Feb; 199():106-13. PubMed ID: 25499917
[TBL] [Abstract][Full Text] [Related]
33. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
Gabizon A; Martin F
Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957
[TBL] [Abstract][Full Text] [Related]
34. Dexamethasone Loaded Liposomes by Thin-Film Hydration and Microfluidic Procedures: Formulation Challenges.
Al-Amin MD; Bellato F; Mastrotto F; Garofalo M; Malfanti A; Salmaso S; Caliceti P
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111100
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of doxorubicin encapsulated in poly(ethylene glycol)-coated liposomes.
Hosoda J; Unezaki S; Maruyama K; Tsuchiya S; Iwatsuru M
Biol Pharm Bull; 1995 Sep; 18(9):1234-7. PubMed ID: 8845812
[TBL] [Abstract][Full Text] [Related]
36. Microfluidic-enabled liposomes elucidate size-dependent transdermal transport.
Hood RR; Kendall EL; Junqueira M; Vreeland WN; Quezado Z; Finkel JC; DeVoe DL
PLoS One; 2014; 9(3):e92978. PubMed ID: 24658111
[TBL] [Abstract][Full Text] [Related]
37. Sequential treatment of oxaliplatin-containing PEGylated liposome together with S-1 improves intratumor distribution of subsequent doses of oxaliplatin-containing PEGylated liposome.
Nakamura H; Doi Y; Abu Lila AS; Nagao A; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2014 May; 87(1):142-51. PubMed ID: 24361534
[TBL] [Abstract][Full Text] [Related]
38. Chain-Length- and Saturation-Tuned Mechanics of Fluid Nanovesicles Direct Tumor Delivery.
Dai Z; Yu M; Yi X; Wu Z; Tian F; Miao Y; Song W; He S; Ahmad E; Guo S; Zhu C; Zhang X; Li Y; Shi X; Wang R; Gan Y
ACS Nano; 2019 Jul; 13(7):7676-7689. PubMed ID: 31187973
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and Characterization of Paclitaxel-Loaded PEGylated Liposomes by the Microfluidics Method.
Jaradat E; Weaver E; Meziane A; Lamprou DA
Mol Pharm; 2023 Dec; 20(12):6184-6196. PubMed ID: 37931072
[TBL] [Abstract][Full Text] [Related]
40. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
